Aligos Therapeutics (NASDAQ:ALGS) Sees Large Volume Increase

Aligos Therapeutics, Inc. (NASDAQ:ALGS) saw unusually-strong trading volume on Monday . Approximately 24,215 shares traded hands during mid-day trading, a decline of 16% from the previous session’s volume of 28,850 shares.The stock last traded at $8.86 and had previously closed at $8.04.

Analysts Set New Price Targets

Separately, HC Wainwright reiterated a “buy” rating and issued a $75.00 target price on shares of Aligos Therapeutics in a research note on Friday, September 20th.

Aligos Therapeutics Trading Down 0.5 %

The firm has a 50 day simple moving average of $12.51 and a two-hundred day simple moving average of $15.51. The company has a market capitalization of $673.31 million, a PE ratio of -6.73 and a beta of 2.18.

Aligos Therapeutics (NASDAQ:ALGS) last posted its quarterly earnings results on Tuesday, August 6th. The company reported $0.75 EPS for the quarter, beating the consensus estimate of ($4.00) by $4.75. The business had revenue of $1.06 million during the quarter. Aligos Therapeutics had a negative return on equity of 110.59% and a negative net margin of 1,100.48%. During the same period in the prior year, the business earned ($10.75) earnings per share. Research analysts expect that Aligos Therapeutics, Inc. will post -8.2 earnings per share for the current fiscal year.

Institutional Trading of Aligos Therapeutics

Several hedge funds have recently modified their holdings of the business. Armistice Capital LLC acquired a new position in Aligos Therapeutics during the fourth quarter worth $4,538,000. Altitude Crest Partners Inc. acquired a new position in Aligos Therapeutics during the fourth quarter worth $1,889,000. Opaleye Management Inc. acquired a new position in Aligos Therapeutics during the fourth quarter worth $861,000. Finally, Acadian Asset Management LLC raised its holdings in Aligos Therapeutics by 26.1% during the second quarter. Acadian Asset Management LLC now owns 829,485 shares of the company’s stock worth $289,000 after purchasing an additional 171,490 shares during the last quarter. 60.43% of the stock is owned by institutional investors and hedge funds.

About Aligos Therapeutics

Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).